Composition comprising mixture of deferoxamine and triglyceride

Abstract

The invention relates to a deferoxamine and triglyceride mixture.

Description

Technical Field

[0001] The present invention relates to a mixture of deferoxamine and triglycerides. Background Art

[0002] Deferoxamine is a class of iron-binding siderophores. For example, relevant reviews can be found in Hider and Kong, Chemistry and Biology of Siderophores, Natural Product Reports (2010), 27(5), 637-657.

[0003] Deferoxamine B (also known as deferoxamine) has been described for use in the cosmetic field. Thus, DE10050155 discloses cosmetics and dermatological formulations containing deferoxamine B.

[0004] In recent years, the concentration of natural oils in formulations has been increasing to meet the demand for products with specific sensory properties. Therefore, antioxidant oils (such as mineral oil and silicone oil) are being gradually replaced by natural-derived oils. These natural oils are rich in essential unsaturated fatty acids and can exhibit various different sensory properties depending on their structure, length, and degree of saturation.

[0005] For example, natural oils are used as emollients and provide functional and skin sensory benefits, especially in terms of their distribution on the skin, which is one of the most important aspects for obtaining a pleasant feeling during and after use.

[0006] In addition, natural emollients are becoming the preferred alternatives because petrochemical products in cosmetics are increasingly being replaced by natural and more sustainable ingredients, and they do not restrict the skin's respiration as synthetic emollients do.

[0007] However, natural oils often suffer from auto-oxidation because high levels of unsaturated fatty acids are the targets of oxidative degradation.

[0008] To solve this problem, formulators use antioxidants and chelating agents to reduce the oxidation process in formulations.

[0009] The use of synthetic antioxidants in cosmetic formulations has been replaced by natural alternatives such as tocopherol, which has become the market benchmark.

[0010] However, tocopherol is difficult to stabilize certain natural lipids, especially at higher concentrations.

[0011] So far, no natural-derived raw materials have been able to overcome this obstacle.

[0012] The object of the present invention is to provide a composition containing a large amount of oil with unsaturated residues, which has enhanced protection against degradation caused by oxidation. Summary of the Invention

[0013] Surprisingly, it has been found that the compositions described subsequently containing at least one desferrioxamine and / or at least one acid addition product of a desferrioxamine or salts thereof are capable of achieving the object of the present invention.

[0014] Accordingly, the present invention relates to a composition according to claim 1 containing at least one desferrioxamine and / or at least one acid addition product of a desferrioxamine or salts thereof and a triglyceride.

[0015] The present invention also relates to the use of at least one desferrioxamine and / or at least one acid addition product of a desferrioxamine or salts thereof in preventing the auto-oxidation of a mixture containing at least two triglycerides according to claim 10.

[0016] The present invention also relates to the use of at least one desferrioxamine and / or at least one acid addition product of a desferrioxamine or salts thereof for reducing and / or preventing the formation of malodorous and / or toxicologically relevant (e.g., allergenic) oxidation degradation products. Such degradation products may be aldehydes, short-chain carboxylic acids, ketones, and mono- and polycyclic hydrocarbons (PAHs), see, for example, Coupland et al., Trends Food Sci Technol. 1996; 7(3):83-91. These oxidation degradation products (among other effects) may increase the risk of sensitization when applied regularly to the skin, see, for example, De Rentiis et al., Contact Dermatitis. 2021; 84(5):317-325; Huang et al., Tenside Surfactants Detergents. 2020; 7(3):230-236; Damevska et al., In: Advances in Integrative Dermatology. John Wiley Blackwell, USA, 2019.; O'Brien et al., Crit Rev Toxicol. 2005; 35(7):609-662.

[0017] The present invention is preferably used to prevent the formation of oxidation degradation products related to toxicology (such as allergens), which are selected from but not limited to the following: primary oxidation products, such as peroxides and hydroperoxides (Christensson et al., Contact Dermatitis. 2012 67(5):247-59), monoterpenes (such as 7-hydroperoxy-3,7-dimethylocta-1,5-diene-3-ol), monoterpene esters, lipids (such as 9-hydroperoxyoctadecadienoic acid, 13-hydroperoxyoctadecadienoic acid), and secondary oxidation products, which may themselves have toxicological relevance or have indirect toxicological relevance through reaction with other components (such as proteins). Such secondary toxicology-related oxidation products are preferably selected from alcohols, aldehydes, ketones, organic acids, esters, amides, amines, alkenes, cycloalkenes, cycloheteroalkanes, cycloheteroalkenes, aromatic compounds, and heteroaromatic compounds.

[0018] In particular, the present invention is preferably used to reduce or prevent the formation of the following substances: oxidation products of cholesterol (such as 7α-hydroxy cholesterol, 7β-hydroxysterol, 5α-cholestane-3β,5α,6β-triol), oxidation products of linalool (such as 2-(5-methyl-5-vinyltetrahydrofuran-2-yl)propan-2-ol, 2,2,6-trimethyl-6-vinyltetrahydro-2H-pyran-3-ol, 2,6-dimethylocta-3,7-diene-2,6-diol, 2,6-dimethylocta-1,7-diene-3,6-diol), and oxidation products of phytosterols (such as 7α-hydroxysitosterol, 7β-hydroxysitosterol, sitosterol-5α,6α-epoxide, sitosterol-5β,6β-epoxide, 7α-hydroxysterol, 7β-hydroxysterol, cholestanetriol, 7-ketosterol, 7-ketositosterol), aldehydes (such as acetaldehyde, dienal, acrolein, 4-hydroxynonenal, and low molecular weight aldehydes having 1 to 8 carbon atoms), and organic acids (such as acetic acid and formic acid).

[0019] An advantage of the present invention is that the composition according to the present invention has good spreadability, so as to achieve uniform distribution and a comfortable feeling on the skin during and after application.

[0020] Another advantage of the present invention is that the composition according to the present invention exhibits a particularly good skin feel and helps to reduce the adhesiveness of the formulation.

[0021] Another advantage of the present invention is that the composition according to the present invention is characterized by a relatively low oily feeling and a satisfactory absorption feeling on the skin.

[0022] Another advantage of the present invention is that the composition according to the present invention exhibits excellent shelf life in terms of emulsion stability and can therefore be stored for a long time.

[0023] Another advantage of the present invention is that the composition according to the present invention has a particularly insignificant effect on the viscosity of the formulation and can be used within a wide pH range.

[0024] Another advantage of the present invention is that the composition according to the present invention can be incorporated into cosmetic formulations in a particularly simple and stable manner.

[0025] Another advantage of the present invention is that the composition according to the present invention contributes to improving the thermal stability of the formulation.

[0026] Another advantage of the present invention is that the composition according to the present invention imparts excellent color stability to the formulation.

[0027] Another advantage of the present invention is that the composition according to the present invention exhibits an improved shelf life in terms of the growth of certain microorganisms and can thus be stored for a long time.

[0028] Accordingly, the present invention relates to a composition comprising

[0029] A) at least one substance selected from desferrioxamine and acid addition products of desferrioxamine or its salts,

[0030] B) a mixture comprising at least two triglycerides,

[0031] wherein the mixture of at least two triglycerides comprised in the composition has an iodine value of 6 cg I / g to 300 cg I / g, preferably 30 cg I / g to 270 cg I / g, more preferably 50 cg I / g to 250 cg I / g, and most preferably 70 cg I / g to 240 cg I / g,

[0032] characterized in that component B) is present in an amount of 5.0 wt% to 80 wt%, preferably 8.0 wt% to 60 wt%, particularly preferably 10.0 wt% to 30 wt%, based on the total composition.

[0033] The iodine value (IV) is a measure of the total number of double bonds in, for example, fats and oils. It is expressed as the number of grams of iodine reacting with the double bonds per 100 grams of the substrate (e.g., fat or oil) or as centigrams of iodine per gram of the substrate.

[0034] The iodine value is preferably determined by a method, preferably by using applied thermometric titration, as described, for example, in Thermo.Titr.Application Note No. H-076 published by Metrohm UK Ltd.

[0035] The iodine value in the context of the present invention refers to the total iodine value of the mixture of all triglycerides contained in the composition of the present invention.

[0036] Unless otherwise stated, all listed percentages (%) are by weight.

[0037] According to the present invention, any desferrioxamine and acid addition products of desferrioxamine or its salts and mixtures thereof may be present in component A).

[0038] In this regard, preferred desferrioxamines are selected from: desferrioxamine A 1A 、desferrioxamine A 1B 、desferrioxamine A2, desferrioxamine B, desferrioxamine D1, desferrioxamine D2, desferrioxamine E, desferrioxamine Et1, desferrioxamine Et2, desferrioxamine Et3, desferrioxamine G1, desferrioxamine G 2A 、desferrioxamine G 2B 、desferrioxamine G 2C 、desferrioxamine H, desferrioxamine N, desferrioxamine P1, desferrioxamine T1, desferrioxamine T2, desferrioxamine T3, desferrioxamine T7, desferrioxamine T8, desferrioxamine Te1, desferrioxamine Te2, desferrioxamine Te3, desferrioxamine X1, desferrioxamine X2, desferrioxamine X3 and desferrioxamine X4, preferably desferrioxamine B, desferrioxamine D1, desferrioxamine D2, desferrioxamine E and desferrioxamine H, particularly preferably desferrioxamine B and desferrioxamine E.

[0039] For nomenclature, if needed, compare Hider and Kong, Chemistry and Biology of Siderophores, Natural Product Reports (2010), 27(5), 637-657.

[0040] According to the present invention, the acid addition product of desferrioxamine or its salt is preferably an acid addition product selected from the following acids: formic acid, aminooxyacetic acid, amino acids, anthraquinonecarboxylic acid, succinic acid, aqueous hydrochloric acid, acetic acid, folic acid, glutaric acid, hydroxamic acid, malonic acid, methanesulfonic acid, nalidixic acid, N-(methylamino)benzoic acid, phenylsuccinic acid, phenylglutaric acid, phosphorous acid, phosphoric acid, hydrogen chloride, sulfurous acid, sulfuric acid, tartaric acid and citric acid, particularly preferably hydrogen chloride, methanesulfonic acid, acetic acid and amino acids.

[0041] According to the preferred composition of the present invention, it is characterized in that component A) is present in an amount of 0.005% to 10.0% by weight, preferably 0.05% to 5.0% by weight, particularly preferably 0.1% to 1.0% by weight, based on the total composition.

[0042] When determining the amount of component A), only the mass of desferrioxamine is considered, while ignoring the counterion of the salt or the acid moiety (if any) in the acid addition product.

[0043] The preferred composition according to the invention is characterized in that the mixture comprised in component B) comprises at least three, preferably at least four, particularly preferably at least five triglycerides.

[0044] The preferred composition according to the invention is characterized in that the mixture comprised in component B) is obtained from a natural source.

[0045] The preferred composition according to the invention is characterized in that the mixture comprised in component B) is selected from natural oils, natural waxes, natural butters, essential oils and mixtures thereof.

[0046] According to the invention, preferably, component B) of the composition of the invention comprises at least one, preferably at least two, particularly preferably at least three natural oils.

[0047] The preferred natural oils contained in component B) of the composition of the present invention are selected from Crambe abyssinica oil, Crambe abyssinica seed oil, acai oil, Euterpe Oleracea (fruit) oil, bitter oil tree oil, Prunus Armeniaca Kernel Oil, argan oil, Persea gratissima oil, almond oil, amaranth vegetable oil, Orbignya Oleifera (Seed) Oil, Adansonia digitata oil, Adansonia digitata Seed Oil, blackberry seed oil, rapeseed oil, carrot macerated oil, Ricinus communis seed oil, Zea mays oil, cranberry seed oil, Oenothera biennis oil, Gossypium herbaceum seed oil, soybean oil, wolfberry seed oil, guava seed oil, Vitis vinifera seed oil, Cannabis sativa seed oil, Helianthus annuus hybrid oil, Linum usitatissimus oil, Linum usitatissimus seed oil, macadamia oil, macadamia seed oil, macadamia seed oil, Passiflora edulis oil, Sclerocarya birrea seed oil, Limnanthes alba seed oil, oat oil, squalane, Olus oil, Simmondsia chinensis seed oil, Oryza sativa bran oil, Helianthus annuus (sunflower) seed oil, sweet almond oil, Olea europaea (olive) fruit oil, Elaeis guineensis oil, palm kernel oil, (Bertholletia excelsa seed oil), Passiflora edulis seed oil, peach kernel oil, pericarp oil, Eugenia uniflora fruit oil, Punica granatum seed oil, cactus seed oil, pumpkin seed oil, Rubus idaeus seed oil, Rosa damascena oil, Rosa damascena flower oil, rosehip seed oil, Cocos nucifera (coconut) oil, hazelnut oil, safflower oil, safflower seed oil, seed oil, sesame oil, tea tree leaf oil, walnut oil, wheat germ oil,

[0048] Including sunflower (seed) oil, coconut oil (Cocos nucifera oil), jojoba (seed) oil (Simmondsia chinensis (seed) oil), sweet almond oil (Prunus amygdalus dulcis oil), castor oil, olive (fruit) oil (Olea europaea (fruit) oil), argan (kernel) oil (Argana spinosa (kernel) oil), avocado oil (Persea gratissima oil), soybean oil (Glycine soja oil), palm oil, palm kernel oil, grape (seed) oil (Vitis vinifera (seed) oil), lavender essential oil (Lavandula angustifolia oil), macadamia (seed) oil (Macadamia ternifolia (seed) oil), tea tree (leaf) oil (Melaleuca alternifolia (leaf) oil), apricot (kernel) oil (Prunus armeniaca (kernel) oil), rosehip (fruit) oil (Rosa canina (fruit) oil), safflower (seed) oil (Carthamus tinctorius (seed) oil), rosemary (leaf) oil (Rosmarinus officinalis (leaf) oil), lemon (peel) oil (Citrus medica limonum (peel) oil), bergamot (fruit) oil (Citrus aurantium bergamia fruit oil), meadowfoam (seed) oil (Limnanthes alba (seed) oil), eucalyptus (leaf) oil (Eucalyptus globulus (leaf) oil), vegetable oil and hemp (seed) oil (Cannabis sativa (seed) oil) are particularly preferred.

[0049] The preferred natural waxes in component B) of the composition of the present invention are selected from carnauba wax (Copernicia cerifera (carnauba) wax), candelilla wax (Euphorbia cerifera (candelilla) wax), beeswax and sunflower seed wax (Helianthus annuus (sunflower) seed wax), hemp wax, almond wax, myrica fruit wax, rice bran wax, ylang-ylang wax, jasmine grandiflorum wax, lavender flower wax, damask rose flower wax and mimosa flower wax.

[0050] The preferred natural oils in component B) of the composition of the present invention are selected from Astrocaryum Murumuru Seed Butter, Astrocaryum vulgare seed butter, cocoa butter (Theobroma cacao seed butter), shea butter (Butyrospermum parkii butter), cupuaçu butter, murumuru butter, Platonia Insignis Seed Butter, chenopodium oil, Garcinia cambogia seed butter, mango seed butter and cardamom nut oil

[0051] The preferred essential oils in component B) of the composition of the present invention are selected from: tea tree oil (Melaleuca alternifolia (tea tree) leaf oil), copaiba oil, agarwood oil (Aquilaria malaccensis oil), anise oil (Pimpinella anisum oil), basil oil, bergamot oil, bergamot fruit oil (Citrus aurantium bergamia fruit oil), birch oil, borage seed oil (Borago officinalis seed oil), camellia seed oil (Camellia japonica seed oil), camellia (seed) oil, camphor oil, hemp flower essential oil, cedarwood oil, chamomile flower oil (Anthemis nobilis flower oil), cinnamon oil, citron oil, citronella oil, coconut oil, eucalyptus oil, eucalyptus leaf oil (Eucalyptus globulus leaf oil), fennel seed oil, garlic oil, geranium oil (Perlagonium graveolens oil), geranium flower oil (Citrus grandis peel oil), ginger oil, grapefruit oil (Citrus grandis oil), grapefruit peel oil (Citrus grandis peel oil), pecan oil, horseradish oil, jasmine oil, juniper berry oil, lavender oil (Lavandula angustifolia oil), lavandin oil (Lavandula hybrida oil), lavender flower oil, lemon oil, lemon peel oil (Citrus medica limonum peel oil), citrus peel oil (Citrus nobilis peel oil), lemon balm oil, moringa oil (Moringa oleifera oil), moringa seed oil (Moringa oleifera seed oil), mustard oil, neem oil, orange oil (Citrus aurantium dulcis oil), orange peel oil (Citrus aurantium dulcis peel oil), oregano oil, patchouli oil (Pogostemon cabal oil), peppermint oil (Mentha piperita oil), peppermint herb oil (Mentha piperita herb oil), pine oil, rose oil, wild rose fruit oil, rosehip oil (Rosa canina fruit oil), rosemary oil, rosemary leaf oil (Rosmarinus officinalis leafoil), rosewood oil, sage oil, sandalwood oil, sassafras oil, peppermint oil, star anise oil, mandarin oil, thyme oil, wheat germ oil (Triticum vulgare germ oil), wintergreen oil, wild mint leaf oil (Mentha arvensis leaf oil), yarrow oil and ylang-ylang oil (Cananga odorata flower oil).

[0052] The composition according to the invention can for example comprise at least one further additional component selected from the group consisting of emollients, emulsifiers, co-emulsifiers, thickeners / viscosity regulators / stabilizers, antioxidants, hydrotropes (or polyols), solids and fillers, pearlescent additives, insect repellents, self-tanning agents, preservatives, conditioners, fragrances, colorants, cosmetic actives, care additives, lipid boosters and solvents.

[0053] It is evident from the term "further additional component" that the components A) and B) comprised in the composition according to the invention are different from said additional components and that components A) and B) do not belong to said additional components.

[0054] Substances which can be used as exemplary representatives of the respective groups are known to the person skilled in the art and can for example be taken from German application DE 102008001788.4. This patent application is hereby incorporated by reference and thus forms part of this disclosure.

[0055] Regarding other optional components and the amounts thereof, express reference is made to the relevant handbooks known to the person skilled in the art, such as K. Schrader, "Grundlagen und Rezepturen der Kosmetika [Fundamentals and Formulations of Cosmetics]", 2nd edition, pages 329 to 341, Hüthig Buch Verlag, Heidelberg.

[0056] The amount of each additive depends on the intended use.

[0057] Typical starting formulations for the relevant applications are known state of the art and are included in the handbooks of the manufacturers of the relevant base materials and actives, for example. These existing formulations can generally be used without modification. However, if desired, the required modifications can be made in a simple and uncomplicated manner by means of simple tests for adjustment and optimization.

[0058] The composition according to the invention can for example be used as a skin care, facial care, head care, body care, intimate care, foot care, hair care, nail care, dental care or oral care product.

[0059] The composition according to the invention can be used, for example, in the form of an emulsion, a suspension, a solution, a cream, an ointment, a paste, a gel, a stick, a spray, a cleaning product, a cosmetic or a sunscreen formulation or a facial wash.

[0060] Preferred compositions according to the invention are emulsions, in particular selected from oil-in-water emulsions and water-in-oil emulsions, particularly preferably oil-in-water emulsions.

[0061] The invention further relates to the use of at least one substance selected from desferrioxamine and acid addition products of desferrioxamine or its salts, in particular desferrioxamine B, for preventing the auto-oxidation of a mixture comprising at least two triglycerides, wherein the mixture of at least two triglycerides comprised in the composition has an iodine value of from 6 cgI / g to 300 cgI / g, preferably from 30 cgI / g to 270 cgI / g, more preferably from 50 cgI / g to 250 cgI / g, most preferably from 70 cgI / g to 240 cgI / g.

[0062] The invention further relates to the use of at least one desferrioxamine and / or at least one acid addition product of desferrioxamine or its salts, in particular desferrioxamine B, for reducing and / or preventing the formation of malodour in a composition, preferably a mixture comprising at least two triglycerides, wherein the mixture of at least two triglycerides comprised in the composition has an iodine value of from 6 cgI / g to 300 cgI / g, preferably from 30 cgI / g to 270 cgI / g, more preferably from 50 cgI / g to 250 cgI / g, most preferably from 70 cgI / g to 240 cgI / g.

[0063] The invention further relates to the use of at least one desferrioxamine and / or at least one acid addition product of desferrioxamine or its salts, in particular desferrioxamine B, for reducing and / or preventing the formation of toxicologically relevant oxidation degradation products in a composition, preferably a mixture comprising at least two triglycerides, wherein the mixture of at least two triglycerides comprised in the composition has an iodine value of from 6 cgI / g to 300 cgI / g, preferably from 30 cgI / g to 270 cgI / g, more preferably from 50 cgI / g to 250 cgI / g, most preferably from 70 cgI / g to 240 cgI / g.

[0064] In the uses according to the invention, preference is given to using the components mentioned above as preferred components in respect of the compositions according to the invention.

[0065] The invention is described below by way of example in the following examples, which are not intended to limit the invention to the embodiments mentioned, the scope of application of which results from the entire description and the claims. Examples

[0066] Example 1:

[0067] To compare the ability of compositions containing a large amount of natural non-hydrogenated oils to resist the oxidation process, different cosmetic compositions (Formulations 1-4) were prepared.

[0068] The oxidation stability was determined via the oxygen level in the headspace of the formulation within a closed system.

[0069] The formulation ingredients in the following compositions (Formulations 1-6) are expressed using English terms in the form of the generally accepted INCI nomenclature. Unless otherwise stated, all concentrations in the examples are expressed as % by weight.

[0070] Formulations 1-4: O / W emulsions

[0071] A total of 4 O / W emulsions were prepared.

[0072] Formulation 1 contains no antioxidant or chelating agent (negative control), and Formulations 2-4 contain deferoxamine, disodium ethylenediaminetetraacetate, or tocopherol, respectively. The pH of all formulations was adjusted to 5.5 with citric acid.

[0073]

[0074]

[0075] The results (Table 1) show that, compared to Comparative Formulation 1, the inventive Formulation 2 (*) containing deferoxamine unexpectedly achieved more effective antioxidant protection, and unexpectedly, its effectiveness was higher than that of the functionally similar comparative substance disodium ethylenediaminetetraacetate (Comparative Formulation 3) and the reference antioxidant tocopherol (Comparative Formulation 4).

[0076] Table 1: Oxidation stability results (average values)

[0077]

[0078] Example 2:

[0079] Compared to the formulation without deferoxamine (Comparative Formulation 1 in Example 1), the formulation containing tocopherol (Comparative Formulation 4 in Example 1), and the formulation containing disodium EDTA (Comparative Formulation 3 in Example 1), a sensory improvement was observed for the inventive formulation (Formulation 2 in Example 1).

[0080] The formation of malodor was tested by observing the putrid odor of each formulation and comparing it with a putrid odor standard control (on a 7-point scale). After storage for a period of time (4 months, 45 °C), the differences between Formulations 1-4 were evaluated by 5 trained testers, with the scoring ranging from 0 (no difference) to 6 (very large difference).

[0081] The spreadability of the formulation was evaluated on the inner side of the forearm. The tests were carried out on the left and right arms in sequence.

[0082] A panel of 5 assessors evaluated the formulation. The evaluation index was the spreadability of the emulsion (we constructed a suitable 5-point scale), which was represented by the area covered after the emulsion was applied in a circular motion 8 times on the forearm (a circle with a diameter of 4 cm) - 0: no spreadability (the emulsion was completely visible, with a significant whitening effect); 1: slight spreadability (the emulsion was visible, with a slight whitening effect); 2: reliable spreadability (the emulsion was not visible, with a weak whitening effect); 3: good spreadability (the emulsion was not visible, no whitening effect, only shiny); 4: very good spreadability (the emulsion was not visible, no whitening effect, no shine).

[0083] The results of the sensory tests were summarized in Table 2.

[0084] Table 2: Sensory scores (mean values)

[0085]

[0086] Compared with the vehicle formulation without deferoxamine (comparative formulation 1) and the formulations containing tocopherol (comparative formulation 4) and disodium EDTA (comparative formulation 3), the emulsion formulation (formulation 2) of the present invention unexpectedly improved the spreadability and reduced the formation of malodor.

[0087] Example 3:

[0088] Compared with the formulation without deferoxamine (comparative formulation 1 in Example 1), the formulation containing tocopherol (comparative formulation 4 in Example 1), and the formulation containing disodium EDTA (comparative formulation 3 in Example 1), a further sensory improvement of the formulation (formulation 2 in Example 1) of the present invention was observed.

[0089] The sensory properties of the formulation were evaluated on the inner side of the forearm. The tests were carried out on the left and right arms in sequence.

[0090] The formulation was evaluated by a panel of 5 assessors. After the emulsion was applied in a circular motion 8 times on the forearm, its adhesiveness and oily skin feeling were evaluated (using an appropriate 5-point scale): 0: low; 1: slight; 2: medium; 3: high; 4: very high).

[0091] The results of the sensory tests were summarized in Table 3.

[0092] Table 3: Sensory scores (mean values)

[0093]

[0094] Compared with the vehicle formulation without deferoxamine (comparative formulation 1) and the formulations containing tocopherol (comparative formulation 4) and disodium EDTA (comparative formulation 3), the emulsion formulation (formulation 2) of the present invention unexpectedly reduces stickiness and the feeling of oily skin.

[0095] Example 4:

[0096] Compared with the formulation without deferoxamine (comparative formulation 1 in Example 1), an improvement in the stability of the formulation of the present invention (formulation 2 in Example 1) was observed.

[0097] After incubation for 1 year at room temperature (in the dark), the stability was evaluated by measuring the viscosity of the formulation (DV Next, Ametek Brookfield).

[0098] The results of the stability test are summarized in Table 4.

[0099] Table 4: Viscosity data

[0100]

[0101] Compared with the vehicle formulation without deferoxamine (comparative formulation 1), the formulation of the present invention (formulation 2) unexpectedly showed a higher viscosity after storage at room temperature for 1 year and thus had higher stability as an emulsion.

[0102] Example formulation

[0103] The formulation ingredients in the following compositions (formulations 1 - 4) are expressed using English terms in the form of the generally accepted INCI nomenclature. All concentrations in the examples are expressed in wt% unless otherwise stated.

[0104] Natural hand cream

[0105]

[0106]

[0107] Natural body lotion

[0108]

[0109]

[0110] Natural oil-control cream

[0111]

[0112] Natural body lotion

[0113]

[0114]

[0115] Natural baby cream

[0116]

[0117] Natural care deodorant stick

[0118]

[0119] Natural green body mask

[0120]

[0121]

[0122] Moisturizing care essence

[0123]

[0124]

[0125] W / O cream

[0126]

[0127] Daily skin softening cream

[0128]

[0129]

[0130] Natural butter cream

[0131]

[0132] Brazilian natural anti-aging cream

[0133]

[0134]

[0135] Natural facial moisturizer

[0136]

[0137]

[0138] Natural anti-aging cream

[0139]

[0140]

[0141] Natural Day Protection Cream

[0142]

[0143]

[0144] Natural Night Cream

[0145]

[0146] Natural Night WO Cream

[0147]

[0148]

[0149] Natural Foot Cream

[0150]

[0151]

[0152] Natural Repair Hand Cream

[0153]

[0154] Natural Warm Foot Cream

[0155]

[0156]

Claims

1. A composition comprising A) at least one substance selected from desferrioxamine and acid addition products of desferrioxamine or its salts, B) a mixture comprising at least two triglycerides, wherein the mixture of at least two triglycerides comprised in the composition has an iodine value of 6 cg I / g to 300 cg I / g, preferably 30 cg I / g to 270 cg I / g, more preferably 50 cg I / g to 250 cg I / g, most preferably 70 cg I / g to 240 cg I / g, It is characterized in that Component B) is present in an amount of 5.0% to 80% by weight, preferably 8.0% to 60% by weight, particularly preferably 10.0% to 30% by weight, based on the total composition.

2. The composition according to claim 1, wherein The deferoxamine is selected from deferoxamine A 1A and deferoxamine A 1B , deferoxamine A2, deferoxamine B, deferoxamine D1, deferoxamine D2, deferoxamine E, deferoxamine Et1, deferoxamine Et2, deferoxamine Et3, deferoxamine G1, deferoxamine G 2A and deferoxamine G 2B and deferoxamine G 2C , deferoxamine H, deferoxamine N, deferoxamine P1, deferoxamine T1, deferoxamine T2, deferoxamine T3, deferoxamine T7, deferoxamine T8, deferoxamine Te1, deferoxamine Te2, deferoxamine Te3, deferoxamine X1, deferoxamine X2, deferoxamine X3 and deferoxamine X4, preferably deferoxamine B, deferoxamine D1, deferoxamine D2, deferoxamine E and deferoxamine H, particularly preferably deferoxamine B and deferoxamine E.

3. The composition according to claim 1 or 2, characterized in that, The acid addition product of desferrioxamine or its salt is an acid addition product selected from the following acids: formic acid, aminooxyacetic acid, amino acids, anthraquinone carboxylic acids, succinic acid, aqueous hydrochloric acid, acetic acid, folic acid, glutaric acid, hydroxamic acid, malonic acid, methanesulfonic acid, nalidixic acid, N-(methylamino)benzoic acid, phenylsuccinic acid, phenylglutaric acid, phosphorous acid, phosphoric acid, sulfurous acid, sulfuric acid, tartaric acid and citric acid.

4. The composition according to at least one of the preceding claims, characterized in that, Component A) is present in an amount of 0.005% to 10.0% by weight, preferably 0.05% to 5.0% by weight, particularly preferably 0.1% to 1.0% by weight, based on the total composition.

5. The composition according to at least one of the preceding claims, characterized in that, The mixture comprised in component B) comprises at least three, preferably at least four, particularly preferably at least five triglycerides.

6. The composition according to at least one of the preceding claims, characterized in that, The mixture comprised in component B) is obtained from a natural source.

7. The composition according to at least one of the preceding claims, characterized in that, The mixture comprised in component B) is selected from natural oils, natural waxes, natural butters, essential oils and mixtures thereof.

8. The composition according to at least one of the preceding claims, characterized in that, The composition is an emulsion, preferably selected from oil-in-water emulsions and water-in-oil emulsions, preferably an oil-in-water emulsion.

9. The composition according to at least one of the preceding claims, characterized in that, There is at least one additional component selected from the following: emollients, emulsifiers, co-emulsifiers, thickeners / viscosity regulators / stabilizers, antioxidants, hydrotropes (or polyols), solids and fillers, pearlescent additives, insect repellents, self-tanning agents, preservatives, conditioners, fragrances, colorants, cosmetic actives, care additives, lipid boosters and solvents.

10. Use of at least one substance selected from deferoxamine and acid addition products of deferoxamine or its salts, in particular deferoxamine B, for preventing the auto-oxidation of a mixture comprising at least two triglycerides, wherein, The mixture of at least two triglycerides comprised in the composition has an iodine value of 6 cg I / g to 300 cg I / g, preferably 30 cg I / g to 270 cg I / g, more preferably 50 cg I / g to 250 cg I / g, most preferably 70 cg I / g to 240 cg I / g.

11. Use of at least one deferoxamine and / or at least one acid addition product of deferoxamine or a salt thereof, in particular deferoxamine B, for reducing and / or preventing the formation of malodors in a composition, preferably a mixture comprising at least two triglycerides, wherein, The mixture of at least two triglycerides comprised in the composition has an iodine value of 6 cg I / g to 300 cg I / g, preferably 30 cg I / g to 270 cg I / g, more preferably 50 cg I / g to 250 cg I / g, most preferably 70 cg I / g to 240 cg I / g.

12. Use of at least one deferoxamine and / or at least one acid addition product of deferoxamine or its salts, in particular deferoxamine B, for reducing and / or preventing the formation of toxicologically relevant oxidation degradation products in a composition, preferably a mixture comprising at least two triglycerides, wherein, The mixture of at least two triglycerides comprised in the composition has an iodine value of 6 cg I / g to 300 cg I / g, preferably 30 cg I / g to 270 cg I / g, more preferably 50 cg I / g to 250 cg I / g, most preferably 70 cg I / g to 240 cg I / g.

Images